Table 1.
Patient characteristics (n = 560)
| IDH | All | mut | mut | mut | mut |
|---|---|---|---|---|---|
| TERT | mut | mut | wt | wt | |
| 1p/19q | codel | intact | codel | intact | |
| Total (n) | 560 | 279 | 24 | 6 | 251 |
| Mean age (y.o.) | 43.5 | 46.4 | 41.8 | 48.2 | 40.3 |
| − 50 | 399 | 178 | 18 | 3 | 200 |
| > 50 | 161 | 101 | 6 | 3 | 51 |
| M/F | 317/243 | 162/117 | 14/10 | 5/1 | 136/115 |
| WHO gradea | |||||
| II | 287 | 145 | 13 | 4 | 125 |
| III | 240 | 134 | 6 | 2 | 98 |
| IV | 33 | 0 | 5 | 0 | 28 |
| Integrated diagnosisa | |||||
| DA | 138 | 0 | 13 | 0 | 125 |
| AA | 104 | 0 | 6 | 0 | 98 |
| OL | 149 | 145 | 0 | 4 | 0 |
| AO | 136 | 134 | 0 | 2 | 0 |
| GBM | 33 | 0 | 5 | 0 | 28 |
| KPS | |||||
| 90–100 | 460 | 238 | 20 | 6 | 196 |
| < 90 | 98 | 41 | 4 | 0 | 53 |
| nd | 2 | 0 | 0 | 0 | 2 |
| Location | |||||
| Supratentorial | 557 | 279 | 24 | 6 | 248 |
| Infratentorial | 3 | 0 | 0 | 0 | 3 |
| CDKN2A | |||||
| Homo Del | 19 | 3 | 1 | 1 | 14 |
| Non-Del | 365 | 187 | 17 | 3 | 158 |
| nd | 176 | 89 | 6 | 2 | 79 |
| RT | |||||
| (+) | 318 | 137 | 17 | 3 | 161 |
| (−) | 241 | 141 | 7 | 3 | 90 |
| nd | 1 | 1 | 0 | 0 | 0 |
| Chemo | |||||
| (+) | 379 | 210 | 16 | 3 | 150 |
| (−) | 180 | 68 | 8 | 3 | 101 |
| nd | 1 | 1 | 0 | 0 | 0 |
| EOR | |||||
| 90–100% | 329 | 179 | 15 | 2 | 133 |
| < 90% | 231 | 100 | 9 | 4 | 118 |
AA, anaplastic astrocytoma, IDH-mutant; AO, anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted; Chemo, Chemotherapy; codel, codeleted; DA, diffuse astrocytoma, IDH-mutant; Del, Deletion; EOR, extent of resection; F, female; GBM, glioblastoma, IDH-mutant; Homo, Homozygous; nd, no data; KPS, Karnofsky Performance Status; M, male; mut, mutated; OL, oligodendrolioma, IDH-mutant and 1p/19q-codeleted; RT, radiation therapy; y.o., years old; wt, wild-type
aDiagnosis based on CNS WHO2016